Mantuano NR, Stanczak MA, de Araújo Oliveira I, Kirchhammer N, Filardy A, Monaco G, Christian Santos R, Carlos Fonseca A,  Fontes M, de Souza Bastos Jr C, et al. (2020). Hyperglycemia enhances cancer  immune evasion by inducing alternative  macrophage polarization through increa-sed O-GlcNAcylation. Cancer Immunol Res, 8, 1262–1272. 

Gray MA, Stanczak MA, Mantuano NR, Xiao H, Pijnenborg JFA, Malaker SA, Weidenbacher PA, Tanzo JT, Ahn G, Woods EC, et al. (2020). Targeted desialylation overcomes glyco-immune checkpoints and potentiates the anticancer immune response in vivo. Nat Chem Biol, online ahead of print. 

Laubli H, Borsig L. (2019) Altered Cell Adhesion and Glycosylation Promote Cancer Immune Suppression and Metastasis. Front Immunol. 10:2120.

Trefny, M.P., Rothschild, S.I., Uhlenbrock, F., Rieder, D., Kasenda, B., Stanczak, M.A., Berner, F., Kashyap, A.S., Kaiser, M., Herzig, P., et al. (2019). A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer. Clin Cancer Res 25, 3026-3034.
 
Adams, O.J., Stanczak, M.A., von Gunten, S., and Laubli, H. (2018). Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer. Glycobiology 28, 640-647.
 
Stanczak, M.A., Siddiqui, S.S., Trefny, M.P., Thommen, D.S., Boligan, K.F., von Gunten, S., Tzankov, A., Tietze, L., Lardinois, D., Heinzelmann-Schwarz, V., et al. (2018). Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J Clin Invest.
 
Laubli, H., Alisson-Silva, F., Stanczak, M.A., Siddiqui, S.S., Deng, L., Verhagen, A., Varki, N., and Varki, A. (2014a). Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs. J Biol Chem 289, 33481-33491.
 
Laubli, H., Pearce, O.M., Schwarz, F., Siddiqui, S.S., Deng, L., Stanczak, M.A., Deng, L., Verhagen, A., Secrest, P., Lusk, C., et al. (2014b). Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proc Natl Acad Sci U S A 111, 14211-14216.